Related Experiment Video
Updated: Jun 19, 2026

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
Published on: October 3, 2019
Loss of TRIM29 mitigates viral myocarditis by attenuating PERK-driven ER stress response in male mice
Junying Wang1, Wenting Lu1, Jerry Zhang1
1Department of Surgery and Immunobiology and Transplant Science Center, Houston Methodist Research Institute, Houston Methodist, Houston, TX, 77030, USA.
Abstract:
Viral myocarditis, an inflammatory disease of the myocardium, is a significant cause of sudden death in children and young adults. The current coronavirus disease 19 pandemic emphasizes the need to understand the pathogenesis mechanisms and potential treatment strategies for viral myocarditis. Here, we found that TRIM29 was highly induced by cardiotropic viruses and promoted protein kinase RNA-like endoplasmic reticulum kinase (PERK)-mediated endoplasmic reticulum (ER) stress, apoptosis, and reactive oxygen species (ROS) responses that promote viral replication in cardiomyocytes in vitro. TRIM29 deficiency protected mice from viral myocarditis by promoting cardiac antiviral functions and reducing PERK-mediated inflammation and immunosuppressive monocytic myeloid-derived suppressor cells (mMDSC) in vivo. Mechanistically, TRIM29 interacted with PERK to promote SUMOylation of PERK to maintain its stability, thereby promoting PERK-mediated signaling pathways. Finally, we demonstrated that the PERK inhibitor GSK2656157 mitigated viral myocarditis by disrupting the TRIM29-PERK connection, thereby bolstering cardiac function, enhancing cardiac antiviral responses, and curbing inflammation and immunosuppressive mMDSC in vivo. Our findings offer insight into how cardiotropic viruses exploit TRIM29-regulated PERK signaling pathways to instigate viral myocarditis, suggesting that targeting the TRIM29-PERK axis could mitigate disease severity.
Insights
Viral myocarditis is worsened by TRIM29, which triggers endoplasmic reticulum (ER) stress and inflammation. Targeting the TRIM29-PERK pathway with GSK2656157 protects against this heart disease.
Area of Science:
- Cardiology
- Virology
- Immunology
Background:
- Viral myocarditis is a serious condition causing sudden death in young individuals.
- Understanding viral myocarditis pathogenesis is crucial, especially during the COVID-19 pandemic.
Purpose of the Study:
- To investigate the role of TRIM29 in viral myocarditis.
- To explore the TRIM29-PERK signaling pathway in cardiac cells and its therapeutic potential.
Main Methods:
- In vitro studies using cardiomyocytes to assess viral induction of TRIM29 and its effects on ER stress, apoptosis, and ROS.
- In vivo studies using mouse models of viral myocarditis to evaluate the impact of TRIM29 deficiency and PERK inhibition.
- Mechanistic studies involving protein interaction and SUMOylation assays to elucidate the TRIM29-PERK relationship.
Main Results:
- Cardiotropic viruses induce TRIM29, promoting PERK-mediated ER stress, apoptosis, ROS, and viral replication in cardiomyocytes.
- TRIM29 deficiency protected mice from viral myocarditis by enhancing cardiac antiviral functions and reducing inflammation and immunosuppressive mMDSC.
- TRIM29 stabilizes PERK via SUMOylation, enhancing PERK-mediated signaling.
Conclusions:
- Cardiotropic viruses exploit the TRIM29-PERK axis to cause viral myocarditis.
- Targeting the TRIM29-PERK interaction with inhibitors like GSK2656157 may be a viable therapeutic strategy for viral myocarditis.

